Triclosan (TCS) is a high-volume chemical used as an antimicrobial ingredient in more than 2000 consumer products, such as toothpaste, cosmetics, kitchenware, and toys. We report that brief exposure to TCS, at relatively low doses, causes low-grade colonic inflammation, increases colitis, and exacerbates colitis-associated colon cancer in mice. Exposure to TCS alters gut microbiota in mice, and its proinflammatory effect is attenuated in germ-free mice. In addition, TCS treatment increases activation of Toll-like receptor 4 (TLR4) signaling in vivo and fails to promote colitis in Tlr4 −/− mice. Together, our results demonstrate that this widely used antimicrobial ingredient could have adverse effects on colonic inflammation and associated colon tumorigenesis through modulation of the gut microbiota and TLR4 signaling. Together, these results highlight the need to reassess the effects of TCS on human health and potentially update policies regulating the use of this widely used antimicrobial.
INTRODUCTION
Triclosan (TCS) is a high-volume chemical used as an antimicrobial additive in more than 2000 consumer products, such as toothpastes, cosmetics, clothes, kitchenware, and toys (1) . Notably, some toothpastes contain 3000 parts per million (ppm) TCS as the active ingredient. Every year, several million pounds of TCS are used in the U.S. market. Because of the high-volume use of this compound, the entire population is exposed to TCS at almost every stage of life (1) . The National Health and Nutrition Examination Survey showed that TCS was detected in ~75% of the urine samples of individuals tested in the United States (2) . The majority of TCS used in commercial applications is ultimately released into the environment. This has led to widespread environmental contamination. For example, TCS is listed among the top 10 pollutants found in U.S. rivers (1) . Because of the ubiquitous presence of TCS, there is an increasing concern regarding its impact on the environment and human health.
Although previous studies have shown the potentially toxic effects of TCS at relatively high doses, its overall health impact at normal usage concentrations is still poorly understood (3) . For this reason, the regulation of TCS use in consumer products was relatively weak until fairly recently. In September 2016, the U.S. Food and Drug Administration (FDA) issued its first regulation of TCS by removing TCS from over-the-counter handwashing products (4) . This decision was mainly based on studies that showed that soaps containing TCS gave no additional health benefit compared to plain soaps (5) . However, because this ruling only affects over-the-counter handwashing products, TCS remains approved by the FDA and the U.S. Environmental Protection Agency for use in hundreds of other consumer products, such as toothpaste (4) . This means that a better understanding of the effects of TCS on human health could have a significant impact on regulatory policies and public health. To date, the effects of TCS on colonic inflammation and associated colon tumorigenesis are unknown. Here, we studied the effects and mechanisms of TCS exposure on these colonic diseases in mouse models.
RESULTS

Exposure to TCS increases plasma concentrations of TCS and its metabolite in mice
We treated mice with a diet containing 10 and 80 ppm TCS for 3 weeks (see diet composition in table S1) and used liquid chromatography tandem mass spectrometry (LC-MS/MS) to measure the plasma concentrations of TCS and TCS glucuronide (a major metabolite of TCS in vivo) (3) . LC-MS/MS analysis showed that the plasma concentration of total TCS in mice was 246 ± 30 nM (26 ± 2 nM TCS plus 220 ± 28 nM TCS glucuronide) for 10 ppm and 2422 ± 345 nM (132 ± 6 nM TCS plus 2290 ± 339 nM TCS glucuronide) for 80 ppm ( fig. S1 ). These concentrations were similar to those reported in the plasma of TCSexposed human volunteers (6, 7) . Therefore, we treated mice with 10 and 80 ppm TCS in diet in the animal experiments described below. the mice treated with 80 ppm TCS had increased spleen weight (P < 0.01; Fig. 1A ), higher plasma concentration of proinflammatory cytokine interleukin-6 (IL-6) (P < 0.05; Fig. 1B ) (but not other cytokines; see fig. S2 ), enhanced gene expression of Il-6 in colon (P < 0.05; Fig. 1C) , and exaggerated crypt damage in colon (P < 0.05; Fig. 1D ), illustrating enhanced systemic and colonic inflammation.
TCS exposure increases colitis in mice
We studied the effect of TCS on development of inflammatory bowel disease (IBD) using a well-established dextran sodium sulfate (DSS)-induced IBD model in mice (see scheme of animal experiment in Fig. 2A ) (8) . We found that exposure to TCS (80 ppm in diet) increased severity of DSS-induced colitis in mice. Compared with vehicletreated DSS mice, the TCS-treated DSS mice had reduced colon length (P < 0.05; Fig. 2B ), and increased crypt damage in the colon (P < 0.01; Fig. 2C ), illustrating enhanced colitis. Proinflammatory immune cells and cytokines contribute to the pathogenesis of IBD (9) . TCS treatment increased infiltration of immune cells, including leukocytes (CD45 + ; P < 0.05), macrophages (CD45 + F4/80 + ; P < 0.01), and neutrophils (CD45 + Gr1 + ; P < 0.05), into the colon [ Fig. 2D ; see strategies of gating and cell identification in fig. S3 , and representative fluorescence-activated cell sorting (FACS) images in fig. S4A ]. In addition, TCS treatment increased plasma concentration of IL-6 (P < 0.05; Fig. 2E ) (the concentrations of other cytokines were not changed; see fig. S4B ) and gene expression of Il-6 in the colon (P < 0.05; Fig. 2F ).
We further studied the effect of low-dose TCS (5 to 10 ppm in diet) on DSS-induced colitis in mice. We found that exposure to 10 ppm TCS exacerbated DSS-induced colitis, as evidenced by enhanced infiltration of immune cells, including leukocytes (CD45 + ; P < 0.001) and macrophages (CD45 + F4/80 + ; P < 0.05), into the colon ( Fig. 2G ; see representative FACS images in fig. S4C ), and crypt damage in the colon (P < 0.01; Fig. 2H ). These observations demonstrate a potent effect of TCS on DSS-induced colitis in mice.
To establish the broader range of validity of the observed procolitis actions of TCS, we studied its effect on colitis in a second model, Il-10 −/− mice (see scheme of animal experiment in Fig. 3A ). Exposure to TCS enhanced infiltration of leukocytes (CD45 + ; P < 0.05) and macrophages (CD45 + F4/80 + ; P < 0.05) into the colon ( Fig. 3B ; see representative FACS images in fig. S5 ), gene expression of Il-6 in the colon (P < 0.05; Fig. 3C ), and crypt damage in the colon (P < 0.05; Fig. 3D ). These results showed that exposure to TCS increased colitis in Il-10 −/− mice, which further validates its pro-IBD effect.
TCS exposure increases colitis-associated colon tumorigenesis in mice
We studied the effect of TCS on colitis-associated colon cancer using an azoxymethane (AOM)/DSS-induced colon cancer model in mice (see scheme of animal experiment in Fig. 4A ) (10) . Compared with vehicle-treated mice, the mice treated with TCS (80 ppm in diet) had enhanced overall mortality, although the effect was not statistically significant (Fig. 4B) . TCS treatment increased average tumor number (P < 0.05), average tumor size (P < 0.05), and total tumor burden (P < 0.05) in mice (Fig. 4C) . Consistent with increased colon tumorigenesis, quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis showed that TCS treatment increased colonic expression of c-myc, axin2, and -catenin (P < 0.05; fig. S6A ), which are genes that promote colon carcinogenesis via the Wnt signaling pathway (11) . Immunohistochemistry validated that the TCS treatment resulted in an increased expression of -catenin, as well as proliferation cell nuclear antigen (PCNA), in colon tumors (P < 0.05; Fig. 4D ). Immune cells and cytokines are important mediators of tumor inflammation (9 fig.  S6B ). TCS treatment also increased plasma concentrations of IL-6 and tumor necrosis factor- (TNF-) (Fig. 4F) , and gene expression of Il-6 and Tnf- in colon tumors (Fig. 4G) . Together, these results demonstrate that TCS exposure increased colon tumorigenesis and tumor inflammation. The results are expressed as means ± SEM. *P < 0.05, **P < 0.01. The statistical significance was determined using one-way analysis of variance (ANOVA).
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We further tested the effect of low-dose TCS on AOM/DSSinduced colon cancer in mice. Treatment with TCS (10 ppm in diet) did not lead to statistically significant increased tumor number, average tumor size, or total tumor size (Fig. 4H) . TCS treatment increased concentration of TNF- in plasma (P < 0.05; Fig. 4I ), gene expression of Tnf- in colon (P < 0.01; Fig. 4J ), and expression of -catenin and PCNA in colon (P < 0.05; fig. S7 ). These results demonstrate a potent effect of TCS on colitis-associated colon tumorigenesis. Histological score (magnification, ×40; n = 5 to 7 per group). The results are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. The statistical significance of two groups was determined using Student's t test or Wilcoxon-Mann-Whitney test, and comparison of three groups was determined using one-way ANOVA.
TCS exposure promotes colonic inflammation through gut microbiota Gut microbiota contributes to colonic inflammation (12) . To explore the action mechanisms of TCS, we studied the impact of TCS exposure on the gut microbiota. After the mice were treated with TCS (80 ppm in diet) for 3 weeks, there was no significant change of total fecal microbial biomass, as analyzed using fecal DNA as a proxy marker ( fig. S8A ) (13) . 16S ribosomal RNA (rRNA) sequencing showed that TCS treatment decreased  diversity of the microbiota, as assessed by phylogenetic diversity (PD) whole tree analysis (P < 0.01; Fig. 5A ), and modulated  diversity of the microbiota, as assessed by principal coordinate analysis (P = 0.002; Fig. 5B ). In addition, TCS exposure altered composition of the microbiota ( The results are expressed as means ± SEM. *P < 0.05, **P < 0.01. The statistical significance was determined using Student's t test or Wilcoxon-Mann-Whitney test, and the statistical analysis of survival was determined using log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test.
abundance of Bifidobacterium, which has been shown to have antiinflammatory effects (P < 0.05; fig. S8B and table S3) (14) . Because TCS reduced the abundance of Bifidobacterium in vivo, we studied whether TCS could directly inhibit the growth of Bifidobacterium in vitro. We cultured Bifidobacterium infantis 272, which is a gut bacterium with known anti-colitis effect (14) , under anaerobic conditions. We found that, compared with vehicle control (dimethyl sulfoxide), treatment with 100 nM TCS inhibited ~30% of B. infantis 272 growth (P < 0.001; fig. S9 ). This suggests a potential direct effect of TCS on gut bacteria in vitro.
To examine the role of the gut microbiota in the actions of TCS, we studied the effects of TCS on basal inflammation in conventionally raised and germ-free mice. To this end, we maintained conventionally raised and germ-free mice on an irradiated diet and treated them with TCS (80 ppm, w/v) or vehicle via drinking water for 3 weeks.
Two-way ANOVA analysis showed that there was a significant interaction between mouse type (conventionally raised versus germ-free mice) and treatment (TCS versus vehicle) on inflammation (P < 0.05). In the conventionally raised mice, TCS treatment caused low-grade colonic inflammation. Enhanced colon length reduction (Fig. 6A) , expression of Il-6 in colon (Fig. 6B) , concentration of IL-6 in plasma (Fig. 6C) , and crypt damage (Fig. 6D) were found. These observations were similar to the results observed via administration of TCS through the diet (Fig. 1) , and some variations could be caused by differences in administration method of TCS (diet versus drinking water) or in diet (unirradiated versus irradiated diet). In contrast, TCS treatment had no effect on basal inflammation in germ-free mice (Fig. 6) . These results confirm that the gut microbiota contributes to the proinflammatory effect of TCS in vivo.
TCS exposure promotes colitis through Toll-like receptor 4 signaling
Toll-like receptors (TLRs) are important mediators of innate immunity and are involved in regulating how host cells interact with the gut microbiota (12) . Using a TLR4 reporter cell line (HEK-Blue mTLR4), we tested the potential of plasma from the TCS-or vehicle-treated DSS mice to activate TLR4. The reporter assay showed that, compared with the plasma from vehicle-treated DSS mice, the plasma from TCS-treated DSS mice showed enhanced activation of TLR4 (P < 0.001; Fig. 7A ). Consistent with the reporter assay result, we found that the plasma from TCS-treated DSS mice had a higher concentration of lipopolysaccharide (LPS), which is a well-known ligand of TLR4 (P < 0.05; Fig. 7B ) (15) . In addition, qPCR analysis of 16S rRNA gene showed that the TCS-treated DSS mice had higher abundance of bacterial DNA in the liver (P < 0.05; Fig. 7C ). Together, these results showed that exposure to TCS increased activation of TLR4 in vivo, in part through increasing the circulating concentrations of bacterial products.
Previous research has suggested that an increased circulating concentration of bacterial products could be caused by a failure in intestinal barrier function (16) . We assessed the effect of TCS on in vivo intestinal barrier function, using a fluorescein isothiocyanate (FITC)-dextran-based intestinal permeability assay. We found that TCS exposure increased leakage of the orally administered FITC-dextran from the gut into the circulation (P < 0.05; Fig. 7D ). This suggests that TCS exposure increases intestinal permeability. We next tested whether TCS treatment alters the expressions of colonic proteins 
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critical for maintaining intestinal perme ability, including occludin, tight junction protein-1 (ZO-1), trefoil factor-3 (TFF3), and mucin-3 (MUC3) (16) . The qRT-PCR analysis showed that only the expression of Occludin was reduced by TCS treatment (P < 0.05; Fig. 7E ). Together, these results show that in the DSS colitis model, TCS treatment disrupted in vivo intestinal barrier function, which led to enhanced translocation of bacterial products from the gut to the systemic circulation and activation of TLR4 in vivo.
To determine the roles of TLR4 in the procolitis effect of TCS, we studied the comparative effects of TCS on DSS-induced colitis in Tlr4 −/− and wild-type (WT) control mice. Two-way ANOVA analysis showed that there was a significant interaction between mouse type (Tlr4 −/− versus WT mice) and treatment (TCS versus vehicle) on DSS-induced colitis (P < 0.05). Notably, TCS treatment increased immune cells and gene expression of Il-6 in colon of WT mice, but such effects were not observed in Tlr4 −/− mice (Fig. 8) . These results confirm that the pro-colitis effect of TCS in vivo is partially dependent on TLR4.
DISCUSSION
TCS is a widely used antimicrobial ingredient and is incorporated into more than 2000 consumer products (1). Here, our central finding is that short-time exposure to low-dose TCS caused low-grade colonic inflammation, and increased colitis and colitis-associated colon cancer in mice, which suggests a potential adverse effect of Right: Histological score. The results are expressed as means ± SEM. n = 5 to 12 per group. *P < 0.05, **P < 0.01, ****P < 0.0001. The statistical significance of the interaction effect between mouse type (conventionally raised versus germ-free mice) and treatment (TCS versus vehicle) on inflammation was determined by two-way ANOVA. this compound on gut health. We found that, after mice were chronically exposed to 10 to 80 ppm TCS via diet, the concentrations of TCS in mouse plasma were comparable or within several folds of the concentrations reported in the plasma of TCS-exposed human volunteers (6, 7) . This supports the idea that the observed pro-colitis and pro-neoplastic effects of TCS in animal experiments could be mimicking responses in human exposure to TCS. In addition, we performed a relatively short-time treatment (several weeks) in our animal experiments; long-term exposure to TCS at lower concentrations might also induce adverse effects on gut health. This is important because humans could be exposed to TCS for many years by using various widely available personal care products. We do acknowledge the challenges associated with using animal models to study human exposure to consumer antimicrobials. The accurate assessment of exposure and absorption of TCS in human populations is largely unknown, and there could be substantial interindividual variations in exposure and metabolism to TCS (3). In addition, a limitation of this study is that we treated mice with TCS via diet or drinking water, whereas humans do not regularly consume TCS, although TCS could be orally absorbed when using TCS-containing toothpaste (6, 7) . Currently, the development of policies for the regulation of TCS is an intensively debated topic (3, 4) . Our study suggests an urgent need to further evaluate the impact of TCS exposure on gut health in preparation for the potential establishment of regulatory policies for this widely used antimicrobial ingredient.
We demonstrated that the gut microbiota contributes to the proinflammatory effects of TCS. We showed that a 3-week exposure of TCS (80 ppm in diet) caused low-grade colonic inflammation, and this phenotype was associated with reduced diversity of the gut microbiota and decreased abundance of beneficial gut bacteria such as Bifidobacterium. We further showed that the enhancing effect of TCS on basal inflammation was abolished in germ-free mice, which confirms that gut microbiota is required for the biological effect of TCS. Our results are largely in agreement with recent studies showing that exposure to low-dose TCS modulated the gut microbiota in fathead minnows (17) , zebrafish (18) , mice (19) , and rats (20) . Notably, a recent human study showed that routine usage of TCS-containing toothpaste modulated the gut microbiota in humans (21) . Inflammation is a hallmark of many metabolic diseases (22) . Given our findings that exposure to TCS increases basal inflammation in vivo, it would be important to test whether exposure to TCS has any detrimental effects on metabolic diseases.
TLRs are important mediators of innate immunity and regulate how host cells interact with the gut microbiota (12). Our results support a model whereby, during DSS-induced colitis, exposure to TCS disrupted in vivo intestinal barrier function, leading to enhanced translocation of TLR4 ligands (such as LPS and other bacterial products) from the gut into the circulation and increased activation of TLR4 signaling in vivo. The pro-colitis effect of TCS was abolished in Tlr4 −/− mice, validating the importance of TLR4 in the biological action of TCS. Previous studies support that TLR4 promotes colitis and colitis-associated colon tumorigenesis (23) . Together, these results suggest that TCS increases colitis through activation of TLR4 signaling. Here, our data showed that when treated with 2% DSS in drinking water for 6 days, vehicle-treated WT mice and Tlr4 −/− mice showed a similar degree of colitis. These results are in agreement with a previous study using a similar DSS treatment protocol in WT and Tlr4 −/− mice (24) . Some previous studies showed that, compared to WT mice, Tlr4 −/− mice had attenuated DSS-induced colitis (25) (26) (27) or enhanced colitis (28) . These inconsistent results could be, in part, due to differences in treatment conditions or in mouse strains. High colonic expressions of TLR4 are usually observed in IBD and colon cancer patients (29, 30) . Our results suggest that individuals with, or prone to, IBD and colon cancer might be more susceptible to the adverse effects of TCS.
In conclusion, our results suggest that TCS, a widely used consumer antimicrobial, could cause adverse effects on colonic inflammation and colon cancer through modulation of the gut microbiota and TLR4 signaling. Further studies are urgently needed to better characterize the effects of TCS exposure on gut health to establish science-based policies for the regulation of this antimicrobial compound in consumer products. Besides TCS, many other high-volume chemicals are also used as antimicrobial ingredients in various personal care and household products. Compared with TCS, less is known about the health effects of other antimicrobials. Our research suggests the importance of evaluating the potential toxic effects of other antimicrobials on gut microbiota and associated colonic diseases to develop safe antimicrobials with minimal adverse impact on human health and the environment.
MATERIALS AND METHODS
Study design
The aim of the study was to define the effects and mechanisms of TCS on colonic inflammation and colitis-associated colon cancer in mice. First, we measured the plasma concentrations of TCS and its metabolite after the mice were chronically exposed to TCS to determine the optimal dose of TCS in animal experiment to reflect human exposures. Next, we studied the effects of TCS exposure on basal inflammation, DSS-induced colitis, Il-10 knockout-induced colitis, and AOM/DSS-induced colitis-associated colon tumorigenesis in mice. Finally, we explored the roles of gut microbiota and innate immune system in the observed effects of TCS. For each animal experiment, the mice were randomized to receive treatments of TCS or vehicle. The number of mice and the method of statistical analysis are described in the figure legends. Primary data are reported in table S5.
Animal experiments
All animal experiments were conducted in accordance with the protocols approved by the Institutional Animal Care and Use Committee of the University of Massachusetts Amherst (protocol 2014-0007) and the University of Wisconsin-Madison (protocol M005599).
Animal protocol 1: Effects of TCS on basal inflammation in mice C57BL/6 male mice (age, 6 weeks) were purchased from Charles River and maintained on a modified AIN-93G diet (see diet composition in table S1) containing 10 to 80 ppm TCS (99%; Alfa Aesar) dissolved in polyethylene glycol 400 (EMD Millipore) as vehicle (0.5% in diet, v/w) or vehicle alone for 3 weeks. At the end of the experiment, the mice were sacrificed, and the blood and colon tissues were collected for analysis of inflammation. The concentrations of TCS and TCS glucuronide in plasma were measured by LC-MS/MS (see LC-MS/MS method in the Supplementary Materials).
Animal protocol 2: Effects of TCS on DSS-induced colitis in mice C57BL/6 male mice (age, 6 weeks) were maintained on diet containing 5 to 80 ppm TCS or vehicle throughout the experiment. After 3 weeks on the diet, the mice were treated with 2% DSS (molecular weight in the range of 36,000 to 50,000 Da MP Biomedicals) in drinking water for 6 to 8 days to induce colitis. At the end of the experiment, the mice were sacrificed for analysis of inflammation (see methods in the Supplementary Materials).
Animal protocol 3: Effects of TCS on colitis in Il-10
−/− mice Il-10 −/− male C57BL/6 mice (B6.129P2-Il10 tm1Cgn /J; age, 5 weeks) were purchased from the Jackson Laboratory. After acclimation for 1 week in the animal facility, the Il-10 −/− mice were treated with diet containing TCS (80 ppm in the diet) or vehicle for 12 weeks, and then the mice were treated with 200 ppm piroxicam (Sigma-Aldrich) through the diet for 1 week to accelerate development of colitis (31) . At the end of the experiment, the mice were sacrificed, and blood and colon tissues were collected for analysis of inflammation.
Animal protocol 4: Effects of TCS on AOM/DSS-induced colon cancer in mice C57BL/6 male mice (age, 6 weeks) were maintained on diet containing TCS (10 and 80 ppm in the diet) or vehicle throughout the experiment. After 3 weeks on the diet, the mice were treated with AOM (10 mg/kg; Sigma-Aldrich) via intraperitoneal injection; after 1 week, the mice were given 2% DSS in drinking water for 1 week. At day 50 after the AOM injection, the mice were sacrificed for analysis of colon tumorigenesis (see methods in the Supplementary Materials).
Animal protocol 5: Effect of TCS on in vivo
intestinal permeability C57BL/6 male mice (age, 6 weeks) were maintained on diet containing 80 ppm TCS or vehicle throughout the experiment. After 3 weeks on the diet, the mice were treated with 2% DSS in drinking water for 7 days to induce colitis. Then, FITC-dextran (600 mg/kg body weight; 70 kDa; Sigma-Aldrich) was administered to mice by oral gavage. After 4 hours, the mice were euthanized, and blood samples were obtained by cardiac puncture and centrifuged at 2000g for 10 min at 4°C to prepare the plasma fraction. Fluorescence intensity of the plasma was quantified using the Synergy 2 Multi-Mode Microplate Reader (BioTek) with an excitation wavelength of 485 nm and an emission wavelength of 528 nm. FITCdextran concentrations in the plasma were determined against a standard curve.
Animal protocol 6: Effects of TCS on DSS-induced colitis in
Tlr4
−/− and WT control mice Tlr4 −/− male mice (B6.B10ScN-Tlr4
lps-del /JthJ; age, 6 to 7 weeks) and control WT C57BL/6 mice (C57BL/6J; age, 6 weeks) were purchased from the Jackson Laboratory. The mice were maintained on diet containing 80 ppm TCS or vehicle throughout the experiment. After 3 weeks on the diet, the mice were treated with 2% DSS in drinking water for 6 days to induce colitis. At the end of the experiment, the mice were sacrificed for analysis of colonic inflammation.
Animal protocol 7: Effects of TCS on gut microbiota in mice C57BL/6 male mice (age, 6 weeks) were maintained on a modified AIN-93G diet containing 80 ppm TCS or vehicle for 3 weeks. At the end of the experiment, the fecal samples were collected for 16S rRNA sequencing (see sequencing method in the Supplementary Materials).
Animal protocol 8: Effects of TCS exposure on basal inflammation in conventionally raised and germ-free mice
Conventionally raised C57BL/6 mice (housed in a conventional animal facility) and germ-free mice (housed in germ-free isolators) were maintained on an irradiated AIN-93G diet (Envigo) and treated with TCS or vehicle via drinking water (80 ppm TCS, w/v; the drinking water was autoclaved and filtered through a 0.22-m filter) for 3 weeks. At the end of the experiment, the mice were sacrificed, and the blood and colon tissues were collected for analysis of inflammation.
Statistical analysis
Data are expressed as means ± SEM. Statistical comparison of two groups was performed using either Student's t test or Wilcoxon-MannWhitney test, and comparison of three groups was analyzed by either one-way parametric ANOVA followed by Tukey's post hoc test (using PROC MIXED) or one-way nonparametric ANOVA (PROC NPAR1WAY) followed by Dunn's post hoc test. Analysis of inflammation in germ-free and Tlr4 −/− mouse experiments (Figs. 6 and 8) according to mouse type and treatment was performed by two-way ANOVA, followed by Tukey-Kramer's method, and H&E histology data in these experiments were analyzed by two-way ANOVA Poisson generalized linear model, followed by the Tukey-Kramer's multiple comparison method. The statistical analyses were performed using SAS statistical software, and P < 0.05 was considered statistically significant.
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